AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12876240
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (Rebif) treatment
Trial: 1906432
Drug: Cibenzoline (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (260 mg/day and 320 mg/day)
Trial: 1906432
Drug: Flecainide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (200 mg/day and 300 mg/day)
Trial: 1906432
Drug: Flecainide (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (long-term treatment after conversion)
Trial: 1906432
Drug: Cibenzoline (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (long-term treatment after conversion)
Trial: 31162588
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNSs) to pregnant women until 6 mo postpartum and child LNSs from 6-24 mo of age (LNS-LNS)
Trial: 31162588
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (IFA) and no child supplement (IFA-Control)
Trial: 29199503
Drug: SMART Arm
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART Arm with outcome-triggered electrical stimulation and usual therapy
Trial: 29199503
Drug: SMART Arm
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART Arm alone and usual therapy
Trial: 29199503
Drug: usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: usual therapy
Trial: 24934070
Drug: Diet soda
RxNorm normalized name: Magadi soda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet soda (200 ml with aspartame and acesulfame potassium)
Trial: 24934070
Drug: Regular soda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular soda (200 ml without sweetener)
Trial: 773301
Drug: Intravenous gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gentamicin by bolus administration (3 to 5 min)
Trial: 773301
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion of gentamicin (2 h)
Trial: 31583436
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg twice daily with chemotherapy
Trial: 31583436
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with chemotherapy
Trial: 23726373
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg ghrelin
Trial: 21366475
Drug: Long-acting injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injectable risperidone (25 to 50 mg every two weeks)
Trial: 21366475
Drug: Oral antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antipsychotics (psychiatrist's choice)
Trial: 19695629
Drug: Active transcutaneous
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcutaneous electrical nerve stimulation for 4 weeks (2 hours daily)
Trial: 19695629
Drug: Sham transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham transcutaneous electrical nerve stimulation for 4 weeks (2 hours daily)
Trial: 9392698
Drug: Ticlopidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (250 mg twice a day)
Trial: 3813145
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg bupivacaine 0.375% without glucose (Group I)
Trial: 3813145
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg bupivacaine 0.375% with 2.5% glucose (Group II)
Trial: 3813145
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg bupivacaine 0.375% with 7.5% glucose (Group III)
Trial: 24344872
Drug: T/iDHT/E2 (Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/iDHT/E2 (Testosterone gel with dutasteride)
Trial: 24344872
Drug: T/DHT/E2 (Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/DHT/E2 (Testosterone gel alone)
Trial: 24344872
Drug: T/DHT/iE2 (Testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/DHT/iE2 (Testosterone gel with anastrazole)
Trial: 21503628
Drug: Forest therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forest therapy camp program
Trial: 21503628
Drug: Normal daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal daily routines (Control)
Trial: 20110084
Drug: duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duloxetine (60 mg/day)
Trial: 16249960
Drug: Citicoline (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (1,000 mg/die intramuscularly) for 2 months
Trial: 16249960
Drug: Citicoline (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (1,000 mg/die intramuscularly) during additional 2-month periods for a total of 16 periods in 8 years
Trial: 12132610
Drug: Zinc picolinate
RxNorm normalized name: Zinc picolinate
DrugBank: Zinc picolinate (DB11175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc picolinate (29 mg orally by capsule 3 times a day for 3 months)
Trial: 10745565
Drug: AngioJet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AngioJet therapy
Trial: 2082492
Drug: Dipyridamole (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (oral and intravenous)
Trial: 7006663
Drug: Good renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Good renal function with haemoglobin above 100 g/l
Trial: 30012187
Drug: Intraoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV)
Trial: 30012187
Drug: Placebo: routinely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: routinely used intraocular infusion with balanced salt solution during routine PPV
Trial: 17442998
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/d) with cisplatin and gemcitabine
Trial: 8607400
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C and E (600 mg/day, orally for 14 days)
Trial: 7165010
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 5.5 gm/m2 daily for 30 days
Trial: 23386016
Drug: Computer‐Assisted Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer‐Assisted Insulin Protocol
Trial: 20457167
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg single oral dose of propranolol (beta-noradrenergic antagonist)
Trial: 15710304
Drug: Formal Elements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formal Elements Art Therapy Scale task
Trial: 11845369
Drug: Active (Ga-As)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active (Ga-As) laser treatment
Trial: 7623991
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (ACEi) - 10 mg enalapril o.d.
Trial: 7623991
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LPD and ACEi
Trial: 31465842
Drug: Membrane-active antiarrhythmic
RxNorm normalized name: Factive
DrugBank: Gemifloxacin (DB01155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Membrane-active antiarrhythmic drugs
Trial: 31465842
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral anticoagulation with non-vitamin K-antagonist oral anticoagulants
Trial: 30910488
Drug: Noninvasive interactive
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive interactive neurostimulation (NIN) therapy
Trial: 25824327
Drug: Ranibizumab or
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab or Bevacizumab (anti-VEGF drugs) administered as needed over a 2-year period.
Trial: 21091083
Drug: FOX (Fitting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOX (Fitting to Outcomes eXpert) software tool for programming cochlear implant processors
Trial: 15542165
Drug: WF10 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WF10 therapy (0.5 ml/kg body weight, diluted in physiological saline or 5% dextrose water, intravenous infusions over 2 h on 5 consecutive days, every 3 weeks for 2 cycles)
Trial: 11103099
Drug: ipriflavone-containing supplement
RxNorm normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipriflavone-containing supplement
Trial: 23803591
Drug: Bisoprolol/hydrochlorothiazide 5/6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol/hydrochlorothiazide 5/6.25 mg (n=89; R)
Trial: 23803591
Drug: Amlodipine/valsartan 5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 5/160 mg (n=94; E)
Trial: 19572934
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) regional caffeine at 10 mg/kg
Trial: 19572934
Drug: Systemic caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic caffeine at 10 mg/kg
Trial: 15497669
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg losartan tablets (Sarvas)
Trial: 15497669
Drug: losartan/hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan/hydrochlorothiazide (50 mg/12.5 mg) (Sarvastan)
Trial: 8164026
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin applied to half of the back for 6 months
Trial: 2452563
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 20 mg rscu-PA bolus followed by 60 mg infusion over 1 hour
Trial: 2452563
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 10 mg rscu-PA bolus followed by 30 mg infusion
Trial: 2452563
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 80 mg rscu-PA
Trial: 29739454
Drug: 1.5% L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% L-menthol application
Trial: 21600759
Drug: Temozolomide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (150 mg/m²/day for 7 days every 2 weeks)
Trial: 21600759
Drug: Dacarbazine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (1000 mg/m²/day on day 1 every 3 weeks)
Trial: 17875806
Drug: Single autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide (100 mg per day during 6 months) (arm B)
Trial: 16421420
Drug: Temozolomide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide (150 mg/m2 for 7 days every other week) and Thalidomide (50 to 400 mg daily)
Trial: 1362556
Drug: Suriclone 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suriclone 0.4 mg tid (young)
Trial: 1362556
Drug: Suriclone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suriclone 0.1 mg and 0.2 mg tid (elderly)
Trial: 3104448
Drug: New micro‐encapsulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New micro‐encapsulated formulation
Trial: 3104448
Drug: All 5
RxNorm normalized name: Levall 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 5 preparations
Trial: 28585182
Drug: Lime powder
RxNorm normalized name: Lime
DrugBank: Lime (citrus) (DB10635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lime powder (LP) treatment for 6 months
Trial: 16365061
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g FOS
Trial: 11299572
Drug: Larval debridement
RxNorm normalized name: Bombyx mori larva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larval debridement therapy (LDT)
Trial: 9058684
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray 0.56 mg per day
Trial: 9058684
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray 0.28 mg per day
Trial: 8364018
Drug: Indobufen 50
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 50 mg BID
Trial: 8364018
Drug: Indobufen 100
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 100 mg BID
Trial: 8364018
Drug: Indobufen 200
RxNorm normalized name: indobufen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 200 mg BID
Trial: 3539127
Drug: lonazolac 300
RxNorm normalized name: lonazolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lonazolac 300 mg b.i.d.
Trial: 3539127
Drug: indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin 75 mg b.i.d.
Trial: 24749843
Drug: Topical fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluorouracil cream
Trial: 23355301
Drug: Rolofylline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolofylline (1 to 60 mg, infused over 1-2 hours)
Trial: 12789232
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (2-week course)
Trial: 10523461
Drug: Particular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particular therapy
Trial: 8821611
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tripotassium dicitrato bismuthate 120 mg qds+tetracycline 500 mg qds+metronidazole 400 mg qds)
Trial: 8821611
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy A (triple therapy+omeprazole 20 mg od)
Trial: 8821611
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy B (triple therapy+omeprazole 40 mg od)
Trial: 7152081
Drug: 0.05% diflorasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% diflorasone diacetate ointment applied once daily
Trial: 7152081
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate ointment applied twice daily
Trial: 26026604
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) treatment
Trial: 24338461
Drug: Intraarticular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular steroid injection
Trial: 20538138
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of Lp(a) distribution (>/=32.9 mg/dl)
Trial: 20538138
Drug: Lowest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest quartile of Lp(a) distribution (<32.9 mg/dl)
Trial: 16368299
Drug: Tomato extract,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato extract, 250 mg Lyc-O-Mato, during an 8-week treatment period
Trial: 9368236
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (200 mg/day for 6 months)
Trial: 9368236
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without magnesium supplementation (control group)
Trial: 1544017
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of antidepressant medication at night
Trial: 1544017
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of medication during the day
Trial: 3929553
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fentanyl (50 micrograms/kg)
Trial: 30326883
Drug: iMOVE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iMOVE therapy
Trial: 27721227
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen supplementation (2 L/min to 3 L/min) with standard hydration (n = 176)
Trial: 18325675
Drug: Augmented Reality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented Reality (AR) as an adjunct to analgesia and sedation
Trial: 18325675
Drug: Basic cognitive
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic cognitive therapy (Control)
Trial: 12925455
Drug: Pexelizumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab 2.0 mg/kg bolus
Trial: 12925455
Drug: Pexelizumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab 2.0 mg/kg bolus plus 0.05 mg/kg per h for 20 hours
Trial: 10800064
Drug: Neoral (cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral (cyclosporin A) at twice the last i.v. dose
Trial: 10800064
Drug: Neoral (cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral (cyclosporin A) at the same last i.v. dose
Trial: 8717398
Drug: Hybrid vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid vaccine combining outer membrane protein F (OprF) and outer membrane protein I (OprI)
Trial: 8717398
Drug: Oral immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunization with recombinant OprI expressing Salmonella dublin
Trial: 1449918
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg three times daily for 28 days
Trial: 1449918
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 20 mg three times daily for 28 days
Trial: 6727272
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 20 mg diltiazem hydrochloride
Trial: 6727272
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 120 mg diltiazem in solution form
Trial: 6727272
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 120 mg diltiazem as two 60-mg sustained-release tablets
Trial: 22229256
Drug: Oral letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral letrozole (2.5 mg/day)
Trial: 21975350
Drug: Oral exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral exemestane (25 mg/day)
Trial: 18304286
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg taken on demand for up to 12 weeks
Trial: 17000812
Drug: Standard combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combined spinal epidural (Std CSE) with hyperbaric bupivacaine 10 mg and intrathecal fentanyl 15 microg
Trial: 17000812
Drug: Sequential combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combined spinal epidural (Seq CSE) with hyperbaric bupivacaine 5 mg and intrathecal fentanyl 15 microg
Trial: 25670917
Drug: Remifentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (2 μg.kg(‐1) bolus, 2‐7 μg.kg(‐1).min(‐1) infusion)
Trial: 25670917
Drug: High-dose sufentanil-sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sufentanil-sevoflurane (control group)
Trial: 25119853
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol supplementation (9 g kg(‐1)) with rapeseed meal (RSM)
Trial: 25119853
Drug: Dietary cholesterol
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary cholesterol supplementation (9 g kg(‐1)) with cottonseed meal (CSM)
Trial: 19262229
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (30 mg/day)
Trial: 17852947
Drug: Once-daily administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily administration of amphotericin B deoxycholate (1 mg/kg)